Skip to main content
Clinical Trials/NCT06472297
NCT06472297
Completed
N/A

Diabetes Prevention Combining CGM and Artificial Intelligence Health Education

University of Southern California1 site in 1 country23 target enrollmentJune 1, 2024

Overview

Phase
N/A
Intervention
The continuous glucose monitoring system
Conditions
Pre-diabetes
Sponsor
University of Southern California
Enrollment
23
Locations
1
Primary Endpoint
Change in Mean Glucose (mg/dL) From Baseline
Status
Completed
Last Updated
3 months ago

Overview

Brief Summary

The objective of this project is to develop a behavioral intervention that combines wearable continuous glucose monitoring (CGM) with smartphone feedback and educational video clips generated by artificial intelligence (AI) software to improve glycemic control among individuals with pre-diabetes. The goal is to prevent transition to type 2 diabetes.

Detailed Description

Video narratives will be provided by Latino community health workers, known as Promotores de Salud (PdS), who will wear and experience the continuous glucose monitoring (CGM) system and its glycemic variability feedback. Study 1 (G1) is a Phase 0 intervention development study, enrolling a sample of 20 Spanish- and/or English-speaking PdS who test positive for pre-diabetes via a finger prick screening. Participants will wear CGM devices for 20 days, during which they will record daily narratives about their experiences with the CGM feedback and their glucose variability. Structured interviews between staff and participants will explore the benefits and barriers of CGM use. These recorded video clips will serve as the foundation for educational cinematic smartphone videos for future interventions. Artificial intelligence (AI) tools will be used to translate the text, audio, and video clips into various languages for broad dissemination. Blood glucose levels in mg/dL will be recorded continuously over the wear period.

Registry
clinicaltrials.gov
Start Date
June 1, 2024
End Date
September 30, 2024
Last Updated
3 months ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

David S Black, PhD

Associate Professor of Population and Public Health Sciences

University of Southern California

Eligibility Criteria

Inclusion Criteria

  • Prediabetes by finger prick blood A1C%
  • Centers for Disease Control and Prevention (CDC) prediabetes risk test score of 5 or higher
  • Willingness to wear CGM sensor
  • Latino community health worker

Exclusion Criteria

  • Currently pregnant
  • Less than 18 years of age, which is adult in California
  • Diagnosed with any disorder that interferes with glucose
  • Influential medical disorder/event affecting ability to participate in study
  • Incompatible smartphone device not pairing with Dexcom G6 app

Arms & Interventions

Unmasked CGM feedback

The CGM system is used by the participant according to manufacturer instructions for the condition interval in their normal living environment.

Intervention: The continuous glucose monitoring system

Outcomes

Primary Outcomes

Change in Mean Glucose (mg/dL) From Baseline

Time Frame: Up to 20 days of continuous CGM wear, comprising two sequential 10-day assessment periods (baseline Phase A and subsequent Phase B).

Mean glucose was derived from continuous glucose monitoring (CGM) data obtained from the Dexcom Clarity system. Raw glucose values were processed and analyzed using the R statistical software package iglu to generate the full CGM variability metrics panel. For each participant, mean glucose was calculated separately for each 10-day assessment period. The outcome measure represents the change in mean glucose, defined as the difference between the baseline (Phase A) 10-day assessment period and the subsequent (Phase B) 10-day assessment period.

Study Sites (1)

Loading locations...

Similar Trials